Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextrothyroxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 11/20 | 0.74 |
| ▸ | THRA known ✓ | P10827 | 7/20 | 0.74 |
| ▸ | USP2 | O75604 | 4/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 7/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | PPARG | P37231 | 5/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.74 |
| ▸ | TTR | P02766 | 2/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | RXRA | P19793 | 2/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextrothyroxine SCHEMBL838270 | 1.00 | USP2 (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL7112166 | 1.00 | USP2 (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL5498887 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL34102 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL582058 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL1995243 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Levothyroxine SCHEMBL1560691 | 0.94 | THRB (0.86) | USP2L3MBTL1THRBMEN1KMT2A | |
| Levothyroxine SCHEMBL4965467 | 0.94 | THRB (0.86) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL15569465 | 0.91 | THRB (0.91) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL4437395 | 0.87 | THRB (0.61) | USP2L3MBTL1THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-3662058-B1 | GENERATION OF OLIGODENDROGENIC NEURAL PROGENITOR CELLS | UNIV HEALTH NETWORK (CA) | 2024-04-24 | — | — | EP | claimed |
| US-11859206-B2 | Generation of oligodendrogenic neural progenitor cells | UNIVERSITY HEALTH NETWORK (CA) | 2024-01-02 | — | — | US | claimed |
| WO-2022204771-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF HYPOTHYROIDISM, AND METHOD | PERACCHI EDSON LUIZ (BR) | 2022-10-06 | — | — | WO | claimed |
| CN-216879247-U | Levothyroxine sodium production is with quantitative conveying equipment | 天津九海医药科技有限公司 | 2022-07-05 | — | — | CN | claimed |
| CN-216834548-U | Filling equipment is used in levothyroxine sodium production | 天津九海医药科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| US-20210024888-A1 | GENERATION OF OLIGODENDROGENIC NEURAL PROGENITOR CELLS | UNIVERSITY HEALTH NETWORK (CA) | 2021-01-28 | — | — | US | claimed |
| US-10792265-B2 | Methods of treating or preventing fibrotic lung diseases | YALE UNIVERSITY (US) | 2020-10-06 | — | — | US | claimed |
| EP-3662058-A1 | GENERATION OF OLIGODENDROGENIC NEURAL PROGENITOR CELLS | University Health Network (CA) | 2020-06-10 | — | — | EP | claimed |
| WO-2019023793-A1 | GENERATION OF OLIGODENDROGENIC NEURAL PROGENITOR CELLS | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-07 | — | — | WO | claimed |
| US-20180369179-A1 | METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES | UNIV YALE (US) | 2018-12-27 | — | — | US | claimed |
| US-9913819-B2 | Methods of treating or preventing fibrotic lung diseases | YALE UNIVERSITY (US) | 2018-03-13 | — | — | US | claimed |
| US-20170105956-A1 | NOVEL METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES | UNIV YALE (US) | 2017-04-20 | — | — | US | claimed |
| WO-2015191841-A1 | NOVEL METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES | YALE UNIVERSITY (US) | 2015-12-17 | — | — | WO | claimed |
| US-8333192-B2 | Dry powder comprising levothyroxine sodium administrated via inhalator | UNI-PHARMA KLEON TSTETIS PHARMACEUTICALS LABORATORIES S.A. (GR) | 2012-12-18 | — | — | US | claimed |
| US-20080178870-A1 | Dry Powder Comprising Levothyroxyne Sodium Administrated Via Inhalator | UNI-PHARMA KLEON TSTETIS PHARMACEUTICALS LABORATORIES S.A. (GR) | 2008-07-31 | — | — | US | claimed |
| EP-1811987-B1 | DRY POWDER COMPRISING LEVOTHYROXINE SODIUM ADMINISTERED VIA INHALATOR | UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB SA (GR) | 2008-04-02 | — | — | EP | claimed |
| EP-1811987-A1 | DRY POWDER COMPRISING LEVOTHYROXINE SODIUM ADMINISTERED VIA INHALATOR | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) | 2007-08-01 | — | — | EP | claimed |
| WO-2006054120-A1 | DRY POWDER COMPRISING LEVOTHYROXINE SODIUM ADMINISTERED VIA INHALATOR | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2006-05-26 | — | — | WO | claimed |
| US-12635957-B2 | Methods and kits for assessing neurological and ophthalmic function and localizing neurological lesions | NEW YORK UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4724053-A1 | PHARMACEUTICAL ORAL SOLID DOSAGE FORMS INCLUDING LIOTHYRONINE AND LEVOTHYROXINE SALTS AND METHODS OF MAKING AND USING THE SAME | Genus Lifesciences Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12544377-B2 | Compounds, compositions and methods of treating or preventing acute lung injury | YALE UNIVERSITY (US) | 2026-02-10 | — | — | US | disclosed |
| US-12514486-B2 | Methods and kits for assessing neurological function and localizing neurological lesions | NEW YORK UNIVERSITY (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4662229-A2 | SOLID DOSAGE FORMS INCLUDING PORCINE THYROID POWDER AND METHODS OF MAKING AND USING THE SAME | Genus Lifesciences Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12274790-B1 | Thyroid hormone oral dosage forms and methods of using the same | Genus Lifesciences Inc. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250098995-A1 | METHODS AND KITS FOR DIAGNOSING, ASSESSING OR QUANTITATING DRUG USE, DRUG ABUSE AND NARCOSIS, INTERNUCLEAR OPHTHALMOPLEGIA, ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD), CHRONIC TRAUMATICENCEPH ALOPATHY,SCHIZOPHRENIA SPECTRUM DISORDERS AND ALCOHOL CONSUMPTION | NEW YORK UNIVERSITY (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2025047787-A1 | FILM PREPARATION CAPABLE OF ADHERING TO ANIMAL ORAL CAVITIES | 株式会社ペティーナ | 2025-03-06 | — | — | WO | disclosed |
| WO-2025047788-A1 | FILM PREPARATION HAVING ADHESIVENESS TO INSIDE OF ANIMAL ORAL CAVITY | 株式会社ペティーナ | 2025-03-06 | — | — | WO | disclosed |
| US-20250057486-A1 | Methods And Kits For Assessing Neurological And Ophthalmic Function And Localizing Neurological Lesions | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2024253724-A1 | PHARMACEUTICAL ORAL SOLID DOSAGE FORMS INCLUDING LIOTHYRONINE AND LEVOTHYROXINE SALTS AND METHODS OF MAKING AND USING THE SAME | Genus Lifesciences Inc. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | disclosed |
| WO-2024229582-A1 | DEVICE AND METHOD FOR DETECTING LOW LEVELS OF THE T4 HORMONE DURING PREGNANCY | UNIVERSIDAD ANDRÉS BELLO (CL) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024192543-A1 | METHOD FOR SELECTING DRUGS FOR THE TREATMENT OF MENTAL HEALTH PATHOLOGIES | NEOMENTE CORP (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20240293585-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240285223-A1 | Methods And Kits For Assessing Neurological Function And Localizing Neurological Lesions | NEW YORK UNIVERSITY (US) | 2024-08-29 | — | — | US | disclosed |
| US-12071516-B2 | Polymeric stabilizing formulations | NANO PRECISION MEDICAL, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2024168411-A1 | FOOD ADDITIVE AND/OR FOOD SUPPLEMENT, PRODUCTION METHOD, FORMULATION OF FUNCTIONAL FOOD AND/OR FOOD SUPPLEMENT, USE | PROTEIMAX BIO TECHNOLOGY ISRAEL LTD (IL) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024167901-A2 | SOLID DOSAGE FORMS INCLUDING PORCINE THYROID POWDER AND METHODS OF MAKING AND USING THE SAME | Genus Lifesciences Inc. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-12016952-B2 | Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition | NEKTAR THERAPEUTICS (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240197770-A1 | COMPOSITIONS AND METHODS FOR TREATING ELASTIC FIBER BREAKDOWN | MATRX THERAPEUTICS CORP (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2024-06-20 | — | — | US | disclosed |
| EP-3612184-B1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING ACUTE LUNG INJURY | UNIV YALE (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240165115-A1 | Compounds, Compositions and Methods of Treating or Preventing Acute Lung Injury | UNIV YALE (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240156920-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | STANDARD OF CARE CORPORATION | 2024-05-16 | — | — | US | disclosed |
| CN-117919171-A | Preparation method of levothyroxine sodium oral liquid | 泊诺(天津)创新医药研究有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-3662058-B1 | GENERATION OF OLIGODENDROGENIC NEURAL PROGENITOR CELLS | UNIV HEALTH NETWORK (CA) | 2024-04-24 | — | — | EP | disclosed |
| CN-111954518-B | Dry pharmaceutical powder composition for inhalation comprising thyroid hormone | 尤利亚·采蒂 | 2024-04-05 | — | — | CN | disclosed |
| US-11944449-B2 | Methods and kits for assessing neurological function and localizing neurological lesions | NEW YORK UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-11938109-B2 | Methods for the preparation of a levothyroxine solution | EMP LEVO US B.V. (NL) | 2024-03-26 | — | — | US | disclosed |
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11890283-B2 | Compounds, compositions and methods of treating or preventing acute lung injury | YALE UNIVERSITY (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2024017423-A1 | PEPTIDE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH APOLIPOPROTEIN AI OR TRANSTHYRETIN INVOLVEMENT | CENTRO DE INGENIERIA GENÉTICA Y BIOTECNOLOGÍA (CU) | 2024-01-25 | — | — | WO | disclosed |
| US-11859206-B2 | Generation of oligodendrogenic neural progenitor cells | UNIVERSITY HEALTH NETWORK (CA) | 2024-01-02 | — | — | US | disclosed |
| US-20230399455-A1 | BIO-FUNCTIONALIZATION OF WATER-SOLUBLE POLY(PHENYLENE EHTYLENE)S | UNIV TEXAS (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-11-21 | — | — | US | disclosed |
| CN-110753546-B | Compounds, compositions and methods for treating or preventing acute lung injury | 耶鲁大学 | 2023-11-10 | — | — | CN | disclosed |
| EP-3659591-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11786460-B2 | Pharmaceutical dry powder composition for inhalation comprising a thyroid hormone | Tseti, Ioulia (GR) | 2023-10-17 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2023-09-07 | — | — | US | disclosed |
| US-11737986-B1 | Thyroid hormone oral dosage forms and methods of using the same | Genus Lifesciences Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230255540-A1 | Methods And Kits For Assessing Neurological Function And Localizing Neurological Lesions | NEW YORK UNIVERSITY (US) | 2023-08-17 | — | — | US | disclosed |
| US-11712420-B1 | Thyroid hormone oral dosage forms and methods of using the same | Genus Lifesciences Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2023115688-A1 | RAPIDLY DISPERSED SUSPENDING COMPOSITION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海奥全生物医药科技有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023090987-A1 | OPTIMISED PROTEIN COMPRISING THE AMINO ACIDS ESSENTIAL FOR HUMAN NUTRITION | Universidad Nacional Autónoma de México (MX) | 2023-05-25 | — | — | WO | disclosed |
| US-11642071-B2 | Methods and kits for assessing neurological function and localizing neurological lesions | NEW YORK UNIVERSITY (US) | 2023-05-09 | — | — | US | disclosed |
| US-11634540-B2 | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method | NEKTAR THERAPEUTICS (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230113413-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | NEKTAR THERAPEUTICS (US) | 2023-04-13 | — | — | US | disclosed |
| CN-115916177-A | Treatment of thyroid hormone-related disorders | 林茨·O·斯科特三世 | 2023-04-04 | — | — | CN | disclosed |
| US-20230075314-A1 | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF | VOYAGER THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| EP-4110286-A1 | POLYMERIC STABILIZING AGENTS FOR IMPLANTABLE DRUG DELIVERY DEVICES | Nano Precision Medical, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-217887665-U | Agitated vessel is used in production of levothyroxine sodium | 天津九海医药科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-217887665-U | Agitated vessel is used in production of levothyroxine sodium | 天津九海医药科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-217893889-U | Storage device is used in production of levothyroxine sodium | 天津九海医药科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115252789-A | Application of RXR agonist and thyroid hormone in preparation of medicine for treating autoimmune diseases | IO治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022204771-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF HYPOTHYROIDISM, AND METHOD | PERACCHI EDSON LUIZ (BR) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022204771-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF HYPOTHYROIDISM, AND METHOD | PERACCHI EDSON LUIZ (BR) | 2022-10-06 | — | — | WO | disclosed |
| US-11446385-B2 | Polymer derivatives having particular atom arrangements | NEKTAR THERAPEUTICS (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220257829-A1 | COMPOSITIONS AND METHODS FOR PREVENTING ALLERGIES | REVIVICOR, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-4029510-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | Kodiak Sciences Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220211700-A1 | Methods for Objective Assessment of Memory, Early Detection of Risk for Alzheimer's Disease, Matching Individuals With Treatments, Monitoring Response to Treatment, and New Methods of Use for Drugs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-07 | — | — | US | disclosed |
| EP-4017524-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | Standard of Care Corporation (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-216834548-U | Filling equipment is used in levothyroxine sodium production | 天津九海医药科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-216834548-U | Filling equipment is used in levothyroxine sodium production | 天津九海医药科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-216835848-U | A loading attachment for production of levothyroxine sodium | 天津九海医药科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-216835848-U | A loading attachment for production of levothyroxine sodium | 天津九海医药科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| EP-4016544-A1 | CREDO LOGGING SYSTEM | Edward Via College of Osteopathic Medicine (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| CN-114470218-A | Treatment of autoimmune diseases with RXR agonists in combination with thyroid hormones | IO治疗公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3781126-B1 | A PHARMACEUTICAL DRY POWDER COMPOSITION FOR INHALATION COMPRISING A THYROID HORMONE | TSETI IOULIA (GR) | 2022-05-04 | — | — | EP | disclosed |
| US-20220096643-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation | KODIAK SCIENCES INC (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220079936-A1 | MULTI-ARM POLYMER PRODRUGS | NEKTAR THERAPEUTICS (US) | 2022-03-17 | — | — | US | disclosed |
| US-20220081512-A1 | POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD | NEKTAR THERAPEUTICS (US) | 2022-03-17 | — | — | US | disclosed |
| EP-3963055-A1 | VECTORIZED ANTIBODIES (VAB) AND USES THEREOF | Voyager Therapeutics, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20220040177-A1 | Compounds, Compositions and Methods of Treating or Preventing Acute Lung Injury | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-10 | — | — | US | disclosed |
| US-11166953-B2 | Compounds, compositions and methods of treating or preventing acute lung injury | YALE UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| CN-106535933-B | Composition for promoting induction of immunity, which contains nuclear receptor ligand, and vaccine pharmaceutical composition | 日东电工株式会社 | 2021-09-17 | — | — | CN | disclosed |
| US-20210177887-A1 | COMPOSITIONS AND METHODS FOR TREATING ELASTIC FIBER BREAKDOWN | MATRX THERAPEUTICS CORP (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210121459-A1 | Compounds, Compositions and Methods of Treating or Preventing Acute Lung Injury | YALE UNIVERSITY | 2021-04-29 | — | — | US | disclosed |
| US-20210077391-A1 | A PHARMACEUTICAL DRY POWDER COMPOSITION FOR INHALATION COMPRISING A THYROID HORMONE | TSETI IOULIA (GR) | 2021-03-18 | — | — | US | disclosed |
| US-20210069113-A1 | SOLID UNIT DOSAGE FORM FOR DOSE INDIVIDUALIZED DRUG DELIVERY | Modavar Pharmaceuticals LLC | 2021-03-11 | — | — | US | disclosed |
| US-10933084-B2 | Compositions and methods for treating elastic fiber breakdown | MatRx Therapeutics Corporation (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3781126-A1 | A PHARMACEUTICAL DRY POWDER COMPOSITION FOR INHALATION COMPRISING A THYROID HORMONE | Tseti, Ioulia (GR) | 2021-02-24 | — | — | EP | disclosed |
| EP-3773614-A1 | COMPOSITIONS AND METHODS FOR TREATING ELASTIC FIBER BREAKDOWN | Matrx Therapeutics Corporation (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210024888-A1 | GENERATION OF OLIGODENDROGENIC NEURAL PROGENITOR CELLS | UNIVERSITY HEALTH NETWORK (CA) | 2021-01-28 | — | — | US | disclosed |
| CN-111954518-A | Pharmaceutical dry powder composition for inhalation comprising thyroid hormone | 尤利亚·采蒂 | 2020-11-17 | — | — | CN | disclosed |
| US-10792265-B2 | Methods of treating or preventing fibrotic lung diseases | YALE UNIVERSITY (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3662058-A1 | GENERATION OF OLIGODENDROGENIC NEURAL PROGENITOR CELLS | University Health Network (CA) | 2020-06-10 | — | — | EP | disclosed |
| US-20200093103-A1 | BREEDING WATER FOR ANGUILLIFORMES AND METHOD FOR REARING ANGUILLIFORMES | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2020-03-26 | — | — | US | disclosed |
| EP-3612184-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING ACUTE LUNG INJURY | Yale University (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20200046664-A1 | METHOD FOR PREPARATION OF LIQUID ORAL COMPOSITION OF L-THYROXIN | FTF PHARMA PRIVATE LTD (IN) | 2020-02-13 | — | — | US | disclosed |
| CN-110753546-A | Compounds, compositions and methods for treating or preventing acute lung injury | 耶鲁大学 | 2020-02-04 | — | — | CN | disclosed |
| EP-3563678-A1 | BREEDING WATER FOR ANGUILLIFORMES AND METHOD FOR REARING ANGUILLIFORMES | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2019-11-06 | — | — | EP | disclosed |
| WO-2019201712-A1 | A PHARMACEUTICAL DRY POWDER COMPOSITION FOR INHALATION COMPRISING A THYROID HORMONE | TSETI IOULIA (GR) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019200274-A1 | COMPOSITIONS AND METHODS FOR TREATING ELASTIC FIBER BREAKDOWN | MatRx Therapeutics Corporation (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190314403-A1 | COMPOSITIONS AND METHODS FOR TREATING ELASTIC FIBER BREAKDOWN | MatRx Therapeutics Corporation | 2019-10-17 | — | — | US | disclosed |
| US-10406108-B1 | Thyroid hormone oral dosage forms and methods of using the same | Genus Lifesciences Inc. (US) | 2019-09-10 | — | — | US | disclosed |
| CN-110139557-A | The cultivation water of Anguilliforme fish and the breeding method of Anguilliforme fish | 株式会社新日本科学 | 2019-08-16 | — | — | CN | disclosed |
| US-10231931-B1 | Thyroid hormone oral dosage forms and methods of using the same | Genus Lifesciences Inc. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2019023793-A1 | GENERATION OF OLIGODENDROGENIC NEURAL PROGENITOR CELLS | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-07 | — | — | WO | disclosed |
| US-20180369179-A1 | METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES | UNIV YALE (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2018195084-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING ACUTE LUNG INJURY | YALE UNIVERSITY (US) | 2018-10-25 | — | — | WO | disclosed |
| EP-2465539-B1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEM IND CO LTD (JP) | 2018-07-11 | — | — | EP | disclosed |
| WO-2018069805-A2 | METHOD FOR PREPARATION OF LIQUID ORAL COMPOSITION OF L-THYROXIN | FTF PHARMA PRIVATE LIMITED (IN) | 2018-04-19 | — | — | WO | disclosed |
| US-9913819-B2 | Methods of treating or preventing fibrotic lung diseases | YALE UNIVERSITY (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170216430-A1 | IMMUNE-INDUCTION-PROMOTING COMPOSITION INCLUDING NUCLEAR RECEPTOR LIGAND, AND VACCINE PHARMACEUTICAL COMPOSITION | NITTO DENKO CORPORATION (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3189853-A1 | IMMUNE-INDUCTION-PROMOTING COMPOSITION INCLUDING NUCLEAR RECEPTOR LIGAND, AND VACCINE PHARMACEUTICAL COMPOSITION | Nitto Denko Corporation (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-20170105956-A1 | NOVEL METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES | UNIV YALE (US) | 2017-04-20 | — | — | US | disclosed |
| EP-2465540-B1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEM IND CO LTD (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-9446055-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| WO-2015191841-A1 | NOVEL METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES | YALE UNIVERSITY (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015158463-A1 | STABLE PHARMACEUTICAL DOSAGE FORMS COMPRISING LEVOTHYROXINE SODIUM | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2015-10-22 | — | — | WO | disclosed |
| EP-2932963-A1 | Stable pharmaceutical dosage forms comprising Levothyroxine sodium | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) | 2015-10-21 | — | — | EP | disclosed |
| US-8900602-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8333192-B2 | Dry powder comprising levothyroxine sodium administrated via inhalator | UNI-PHARMA KLEON TSTETIS PHARMACEUTICALS LABORATORIES S.A. (GR) | 2012-12-18 | — | — | US | disclosed |
| US-8318712-B2 | Concentrated liquid thyroid hormone composition | INTERVET INTERNATIONAL B.V. (NL) | 2012-11-27 | — | — | US | disclosed |
| US-20120165413-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120156261-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| EP-2465539-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465540-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-1973524-B1 | CONCENTRATED LIQUID THYROID HORMONE COMPOSITION | INTERVET INT BV (NL) | 2011-08-10 | — | — | EP | disclosed |
| US-20090270507-A1 | Concentrated Liquid Thyroid Hormone Composition | INTERVET INTERNATIONAL B.V. (NL) | 2009-10-29 | — | — | US | disclosed |
| EP-1973524-A1 | CONCENTRATED LIQUID THYROID HORMONE COMPOSITION | Intervet International BV (NL) | 2008-10-01 | — | — | EP | disclosed |
| US-20080178870-A1 | Dry Powder Comprising Levothyroxyne Sodium Administrated Via Inhalator | UNI-PHARMA KLEON TSTETIS PHARMACEUTICALS LABORATORIES S.A. (GR) | 2008-07-31 | — | — | US | disclosed |
| EP-1811987-B1 | DRY POWDER COMPRISING LEVOTHYROXINE SODIUM ADMINISTERED VIA INHALATOR | UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB SA (GR) | 2008-04-02 | — | — | EP | disclosed |
| EP-1811987-A1 | DRY POWDER COMPRISING LEVOTHYROXINE SODIUM ADMINISTERED VIA INHALATOR | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007077252-A1 | CONCENTRATED LIQUID THYROID HORMONE COMPOSITION | INTERVET INTERNATIONAL B.V. (NL) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006054120-A1 | DRY POWDER COMPRISING LEVOTHYROXINE SODIUM ADMINISTERED VIA INHALATOR | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2006-05-26 | — | — | WO | disclosed |
| EP-1267999-A4 | STABLE THYROID HORMONE PREPARATIONS AND METHOD OF MAKING SAME | MOVA PHARMACEUTICAL CORP (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1267999-A1 | STABLE THYROID HORMONE PREPARATIONS AND METHOD OF MAKING SAME | Mova Pharmaceutical Corporation (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6399101-B1 | LEVOTHYROXINE SODIUM AND SILICIFIED MICROCRYSTALLINE CELLULOSE; TABLETS; LIGHT, HEAT, AND HUMIDITY STABLE | MOVA PHARMACEUTICAL CORP. | 2002-06-04 | — | — | US | disclosed |
| WO-2001074448-A1 | STABLE THYROID HORMONE PREPARATIONS AND METHOD OF MAKING SAME | MOVA PHARMACEUTICAL CORPORATION (US) | 2001-10-11 | — | — | WO | disclosed |
| US-5225204-A | Stable dosage of levothyroxine sodium and process of production | KNOLL BV (NL) | 1993-07-06 | — | — | US | disclosed |
| US-5225204-A | Stable dosage of levothyroxine sodium and process of production | KNOLL BV (NL) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (32 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938109-B2 | Methods for the preparation of a levothyroxine solution | TPO, TSHR, TRHDE | THRB 5/4885THRA 4/4885USP2 2327/4885 |
| US-11712420-B1 | Thyroid hormone oral dosage forms and methods of using the same | TPO, SHBG, TSHR | THRB 7/4885THRA 4/4885USP2 1020/4885 |
| US-20090270507-A1 | Concentrated Liquid Thyroid Hormone Composition | TSHR, TPO, TRHDE | THRB 4/4885THRA 6/4885USP2 1425/4885 |
| US-20240293585-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | ACP1, PHOSPHO1, PARG | THRB 4808/4885THRA 4481/4885USP2 2285/4885 |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | THRB 3455/4885THRA 2808/4885USP2 1536/4885 |
| US-20220040177-A1 | Compounds, Compositions and Methods of Treating or Preventing Acute Lung Injury | MAP3K3, MAPKAPK3, MAP3K2 | THRB 4339/4885THRA 4596/4885USP2 502/4885 |
| US-12544377-B2 | Compounds, compositions and methods of treating or preventing acute lung injury | MAP3K3, MAP3K13, MAP3K2 | THRB 2860/4885THRA 3980/4885USP2 655/4885 |
| US-12274790-B1 | Thyroid hormone oral dosage forms and methods of using the same | TPO, TSHR, SHBG | THRB 7/4885THRA 4/4885USP2 746/4885 |
| US-20230399455-A1 | BIO-FUNCTIONALIZATION OF WATER-SOLUBLE POLY(PHENYLENE EHTYLENE)S | PGLS, EPCAM, CD69 | THRB 1543/4885THRA 1394/4885USP2 2014/4885 |
| US-20240156920-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | MMP1, MMP2, MMP8 | THRB 4452/4885THRA 4653/4885USP2 493/4885 |
| US-11737986-B1 | Thyroid hormone oral dosage forms and methods of using the same | TPO, SHBG, TSHR | THRB 7/4885THRA 4/4885USP2 1020/4885 |
| US-11446385-B2 | Polymer derivatives having particular atom arrangements | CD44, PIGO, PGLS | THRB 4719/4885THRA 4238/4885USP2 1677/4885 |
| US-12071516-B2 | Polymeric stabilizing formulations | VEGFA, CD44, CFTR | THRB 4811/4885THRA 4073/4885USP2 2250/4885 |
| US-20220096643-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation | PHOSPHO1, PCTP, SGMS1 | THRB 4327/4885THRA 3797/4885USP2 2138/4885 |
| US-20210121459-A1 | Compounds, Compositions and Methods of Treating or Preventing Acute Lung Injury | MAP3K3, MAPKAPK3, MAP3K2 | THRB 4339/4885THRA 4596/4885USP2 502/4885 |
| US-12635957-B2 | Methods and kits for assessing neurological and ophthalmic function and localizing neurological lesions | VGF, CHAT, PYGB | THRB 1499/4885THRA 1713/4885USP2 852/4885 |
| US-20200046664-A1 | METHOD FOR PREPARATION OF LIQUID ORAL COMPOSITION OF L-THYROXIN | TPO, TSHR, THOP1 | THRB 16/4885THRA 7/4885USP2 4089/4885 |
| US-20240165115-A1 | Compounds, Compositions and Methods of Treating or Preventing Acute Lung Injury | MAP3K3, MAPKAPK3, MAP3K2 | THRB 4339/4885THRA 4596/4885USP2 502/4885 |
| US-11166953-B2 | Compounds, compositions and methods of treating or preventing acute lung injury | MAP3K3, MAPKAPK3, MAP3K2 | THRB 4339/4885THRA 4596/4885USP2 502/4885 |
| US-20220081512-A1 | POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD | ASPH, ALDH1A1, ADH1C | THRB 2405/4885THRA 1309/4885USP2 850/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | THRB 1120/4885THRA 2266/4885USP2 1595/4885 |
| US-20230113413-A1 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | CD44, PIGO, PGLS | THRB 4719/4885THRA 4238/4885USP2 1677/4885 |
| US-10231931-B1 | Thyroid hormone oral dosage forms and methods of using the same | TPO, TSHR, SHBG | THRB 7/4885THRA 4/4885USP2 746/4885 |
| US-11634540-B2 | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method | ASPH, ALDH1A1, ADH1C | THRB 2405/4885THRA 1309/4885USP2 850/4885 |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | THRB 3455/4885THRA 2808/4885USP2 1536/4885 |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | PHOSPHO1, MSN, ZW10 | THRB 3455/4885THRA 2808/4885USP2 1536/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | THRB 1120/4885THRA 2266/4885USP2 1595/4885 |
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | THRB 3438/4885THRA 2443/4885USP2 651/4885 |
| US-12016952-B2 | Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition | POLM, OGG1, COPE | THRB 3106/4885THRA 2554/4885USP2 765/4885 |
| US-10406108-B1 | Thyroid hormone oral dosage forms and methods of using the same | TPO, TSHR, SHBG | THRB 7/4885THRA 4/4885USP2 746/4885 |
| US-20220079936-A1 | MULTI-ARM POLYMER PRODRUGS | PAICS, CD38, ENTPD1 | THRB 4274/4885THRA 3731/4885USP2 2533/4885 |
| US-11890283-B2 | Compounds, compositions and methods of treating or preventing acute lung injury | MAP3K3, MAPKAPK3, MAP3K2 | THRB 4339/4885THRA 4596/4885USP2 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.